Vanguard Group Inc Cyclo Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 396,658 shares of CYTH stock, worth $507,722. This represents 0.0% of its overall portfolio holdings.
Number of Shares
396,658
Previous 355,223
11.66%
Holding current value
$507,722
Previous $564,000
2.3%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CYTH
# of Institutions
22Shares Held
2.16MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA854KShares$1.09 Million0.47% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$615,3063.08% of portfolio
-
Geode Capital Management, LLC Boston, MA160KShares$204,4780.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$140,82957.89% of portfolio
-
State Street Corp Boston, MA39.5KShares$50,5980.0% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $10.8M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...